REHOVOT, Israel, July 21, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (NASDAQ:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced the closing of its public offering of 4,524,698 ordinary shares at a price to the public of $17.00 per share, which includes 590,178 shares purchased pursuant to the full exercise of the underwriters' option to purchase additional shares. The gross proceeds to NeuroDerm were approximately $77 million. NeuroDerm offered all of the ordinary shares. The company plans to use the net proceeds from the offering to fund its ND0612H and ND0612L product candidates through completion of its planned clinical trials and the regulatory approval process in the European Union and the United States, the clinical and regulatory development of its ND0701 product candidate, and general research and development of its product candidates, including the development of the devices related to its product candidates.
Jefferies LLC and Cowen and Company, LLC acted as the book-running managers for the offering and Raymond James & Associates, Inc. and Roth Capital Partners, LLC acted as co-managers.
The Securities and Exchange Commission declared effective a registration statement relating to these securities on July 15, 2015. The offering was made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained from either: Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Ave, 2nd Floor, New York, NY 10022, phone: 877-547-6340, email: Prospectus_Department@Jefferies.com, or Cowen and Company, LLC, Attn: Prospectus Department, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, phone: 631-274-2806, fax: 631-254-7140.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
NeuroDerm is a clinical-stage pharmaceutical company developing central nervous system (CNS) product candidates that are designed to overcome major deficiencies of current treatments and achieve enhanced clinical efficacy through continuous, controlled administration. NeuroDerm is headquartered in the Weizmann Science Park in Rehovot, Israel.
Oded S. Lieberman, PhD MBA, CEO
Tel.: +972-8-946 2729
Cell: +1-617-517 6077
U.S. Investor Contact:
Lazar Partners Ltd.